Standout Papers

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractor... 2020 2026 2022 2024246
  1. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial (2020)
    Shaji Kumar, Simon J. Harrison et al. The Lancet Oncology

Immediate Impact

3 from Science/Nature 56 standout
Sub-graph 1 of 24

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Cell death
2024 Standout
2 intermediate papers

Works of Inho Kim being referenced

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
2020 Standout
Efficacy Of Ruxolitinib In Korean Myelofibrosis Patients and Cases Complicated TB Lymphadenitis During The Treatment
2013

Author Peers

Author Last Decade Papers Cites
Inho Kim 841 490 271 523 176 1.6k
Hawk Kim 867 434 337 340 110 1.4k
Seonyang Park 647 303 179 384 132 1.5k
Atul Sharma 460 536 250 446 175 1.6k
Kazuteru Ohashi 920 332 520 427 129 1.9k
H. Kronenberg 823 253 312 284 125 1.8k
Sevgi Yetgin 496 321 180 595 109 1.8k
Takayuki Saitoh 803 336 434 575 144 1.9k
Hongsheng Zhou 730 303 384 559 125 1.6k
Hyun‐Sook Chi 701 349 254 272 98 1.4k
Noriko Doki 862 307 213 383 174 1.5k

All Works

Loading papers...

Rankless by CCL
2026